Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical ...
JOHNSON CITY, Tenn., Aug. 7, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results